Enrico Santinelli , Maria Rosaria Pascale , Zhuoer Xie , Talha Badar , Maximilian F. Stahl , Jan P. Bewersdorf , Carmelo Gurnari , Amer M. Zeidan
{"title":"Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution","authors":"Enrico Santinelli , Maria Rosaria Pascale , Zhuoer Xie , Talha Badar , Maximilian F. Stahl , Jan P. Bewersdorf , Carmelo Gurnari , Amer M. Zeidan","doi":"10.1016/j.blre.2023.101130","DOIUrl":null,"url":null,"abstract":"<div><p><span>In recent years, the therapeutic landscape of myeloid malignancies<span> has been completely revolutionized by the introduction of several new drugs<span>, targeting molecular alterations or pathways crucial for leukemia cells<span> survival. Particularly, many agents targeting apoptosis have been investigated in both pre-clinical and clinical studies. For instance, </span></span></span></span>venetoclax<span><span>, a pro-apoptotic agent active on BCL-2 signaling, has been successfully used in the treatment of </span>acute myeloid leukemia<span> (AML). The impressive results achieved in this context have made the apoptotic pathway an attractive target also in other myeloid neoplasms, translating the experience of AML. Therefore, several drugs are now under investigation either as single or in combination strategies, due to their synergistic efficacy and capacity to overcome resistance.</span></span></p><p>In this paper, we will review the mechanisms of apoptosis and the specific drugs currently used and under investigation for the treatment of myeloid neoplasia, identifying critical research necessities for the upcoming years.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000917","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
In recent years, the therapeutic landscape of myeloid malignancies has been completely revolutionized by the introduction of several new drugs, targeting molecular alterations or pathways crucial for leukemia cells survival. Particularly, many agents targeting apoptosis have been investigated in both pre-clinical and clinical studies. For instance, venetoclax, a pro-apoptotic agent active on BCL-2 signaling, has been successfully used in the treatment of acute myeloid leukemia (AML). The impressive results achieved in this context have made the apoptotic pathway an attractive target also in other myeloid neoplasms, translating the experience of AML. Therefore, several drugs are now under investigation either as single or in combination strategies, due to their synergistic efficacy and capacity to overcome resistance.
In this paper, we will review the mechanisms of apoptosis and the specific drugs currently used and under investigation for the treatment of myeloid neoplasia, identifying critical research necessities for the upcoming years.
期刊介绍:
Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.